Patients with advanced lung cancer who received an immunotherapy drug plus standard chemotherapy lived significantly longer than those who got chemo alone, according to a new study that is expected to change the way such patients are treated.
By Laurie McGinley, Washington Post
Mon, 04/16/2018 - 7:15am
Patients with advanced lung cancer who received an immunotherapy drug plus standard chemotherapy lived significantly longer than those who got chemo alone, according to a new study that is expected to change the way such patients are treated.